Jaguar Health, Inc. (JAGX)
0.319
-0.05
(-12.91%)
USD |
NASDAQ |
Sep 10, 16:00
0.3237
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.549M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -99.46% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 0.0045 |
| Price to Book Value | 0.2343 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 2.767 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.0% |
Profile
| Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA. |
| URL | http://www.jaguar.health |
| Investor Relations URL | https://jaguarhealth.gcs-web.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 12, 2026 (est.) |
| Last Earnings Release | Aug. 19, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the following segments: Animal Health and Human Health. The Animal Health segment is focused on development and commercialization of prescription and non-prescription products for companion and production animals. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA. |
| URL | http://www.jaguar.health |
| Investor Relations URL | https://jaguarhealth.gcs-web.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 12, 2026 (est.) |
| Last Earnings Release | Aug. 19, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |